Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Breast Neoplasms 37Prostatic Neoplasms 12Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Liver Neoplasms 3Fibrosis 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Intraductal, Noninfiltrating 3Uterine Cervical Neoplasms 2Thyroid Nodule 2Stomach Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pleural Effusion, Malignant 2Neoplasms 2Mouth Neoplasms 2Melanoma 2Lymphoma 2Lymphedema 2Leukemia, Myeloid, Acute 2Leukemia 2Inflammatory Breast Neoplasms 2Infertility 2Hodgkin Disease 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Medullary 2Carcinoma, Hepatocellular 2Anatomic Stage III Breast Cancer AJCC v8 2

Interventions

Magnetic Resonance Spectroscopy 9Iodine-131 8Thyrotropin Alfa 5trametinib 3lenvatinib 3cabozantinib 3X-Rays 3Sunitinib 3Specimen Handling 3Fluorodeoxyglucose F18 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3vandetanib 2dabrafenib 2Trastuzumab 2Sorafenib 2Rosiglitazone 2Radiotherapy 2Interviews as Topic 2Gefitinib 2Everolimus 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1tremelimumab 1tipifarnib 1tanespimycin 1spartalizumab 1selpercatinib 1sargramostim 1romidepsin 1pembrolizumab 1pazopanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Follicular × High-Energy Shock Waves × Clear all
NCT06440850 2026-02-02

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

City of Hope Medical Center

Phase 2 Recruiting
21 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡